Zacks Research Forecasts Revvity’s Q2 Earnings (NYSE:RVTY)

Revvity Inc. (NYSE:RVTY) – Equities researchers at Zacks Research increased their Q2 2026 earnings per share (EPS) estimates for Revvity in a research report issued on Monday, February 23rd. Zacks Research analyst Team now anticipates that the company will post earnings per share of $1.31 for the quarter, up from their prior forecast of $1.29. The consensus estimate for Revvity’s current full-year earnings is $4.94 per share. Zacks Research also issued estimates for Revvity’s Q3 2026 earnings at $1.34 EPS, FY2026 earnings at $5.36 EPS and Q1 2027 earnings at $1.28 EPS.

RVTY has been the subject of a number of other reports. Jefferies Financial Group raised their price objective on shares of Revvity from $100.00 to $105.00 and gave the stock a “hold” rating in a research note on Monday, February 2nd. Weiss Ratings reiterated a “sell (d)” rating on shares of Revvity in a report on Monday, December 29th. The Goldman Sachs Group initiated coverage on Revvity in a report on Tuesday, December 9th. They issued a “neutral” rating and a $105.00 price target for the company. Evercore increased their price objective on Revvity from $112.00 to $118.00 and gave the company an “outperform” rating in a research note on Tuesday, February 3rd. Finally, Barclays lifted their price objective on Revvity from $115.00 to $118.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 3rd. Five equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $113.67.

Revvity Stock Performance

Shares of RVTY opened at $98.97 on Thursday. Revvity has a 12-month low of $81.36 and a 12-month high of $120.39. The stock has a market cap of $11.06 billion, a P/E ratio of 47.58, a PEG ratio of 2.07 and a beta of 1.07. The company has a current ratio of 1.68, a quick ratio of 1.40 and a debt-to-equity ratio of 0.36. The company has a 50-day moving average of $103.27 and a two-hundred day moving average of $96.32.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Monday, February 2nd. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.55 by $0.15. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The business had revenue of $772.06 million for the quarter, compared to analyst estimates of $759.81 million. During the same period in the previous year, the firm earned $1.42 EPS. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS.

Institutional Trading of Revvity

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC increased its stake in shares of Revvity by 5.2% during the 1st quarter. AQR Capital Management LLC now owns 8,449 shares of the company’s stock valued at $883,000 after acquiring an additional 420 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Revvity by 6.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,776 shares of the company’s stock worth $1,246,000 after purchasing an additional 744 shares during the last quarter. Millennium Management LLC raised its stake in Revvity by 102.0% during the first quarter. Millennium Management LLC now owns 69,401 shares of the company’s stock worth $7,343,000 after purchasing an additional 35,048 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Revvity by 45.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 607,104 shares of the company’s stock valued at $64,232,000 after purchasing an additional 189,871 shares during the last quarter. Finally, Focus Partners Wealth grew its stake in shares of Revvity by 13.0% during the 1st quarter. Focus Partners Wealth now owns 7,028 shares of the company’s stock valued at $744,000 after buying an additional 811 shares during the period. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 8th. Investors of record on Friday, April 17th will be given a dividend of $0.07 per share. The ex-dividend date is Friday, April 17th. This represents a $0.28 annualized dividend and a yield of 0.3%. Revvity’s dividend payout ratio is 13.46%.

Revvity News Roundup

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Zacks Research raised Revvity’s near-term and FY2026 estimates (Q2 2026 to $1.31, Q3 2026 to $1.34 and FY2026 to $5.36), reflecting stronger-than-expected momentum and aligning with company guidance; higher FY2026 estimates support revenue/earnings beat narratives. MarketBeat: Revvity estimates
• Positive Sentiment: Investors are also responding to coverage of Revvity’s strong Q4 beat and upbeat 2026 outlook — the company reported quarterly EPS and revenue above consensus and provided FY2026 guidance that analysts view as constructive for near-term growth. How Investors May Respond To Revvity Strong Q4 Beat
• Neutral Sentiment: Third‑party comparisons and sector context (e.g., Progyny vs. Revvity) are circulating but are unlikely to materially move the stock absent new company-specific guidance or results. Financial Comparison: Progyny vs. Revvity
• Negative Sentiment: Zacks trimmed several 2027 estimates (Q1 2026 cut to $1.03, Q2/Q3 2027 cuts and FY2027 reduced to $5.90 from $5.97), which temper longer‑term growth expectations and could cap multiple expansion if analysts continue to lower longer-dated forecasts. MarketBeat: Revvity estimates

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.